<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font24 { font-size : 24; } .font25 { font-size : 25; } .font11 { font-size : 11; } .font28 { font-size : 28; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font31 { font-size : 31; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font31">HCV </span>
   <span class="font28">patients </span>
   <span class="font25">disease </span>
   <span class="font24">glomerular </span>
   <span class="font20">antiviral </span>
   <span class="font20">kidney </span>
   <span class="font19">(%) </span>
   <span class="font19">[]. </span>
   <span class="font19">therapy </span>
   <span class="font16">clinical </span>
   <span class="font16">hepatitis </span>
   <span class="font16">treatment </span>
   <span class="font16">cryoglobulinemic </span>
   <span class="font15">{border-style </span>
   <span class="font15">DAAs </span>
   <span class="font15">chronic </span>
   <span class="font15">glomerulonephritis </span>
   <span class="font15">px;} </span>
   <span class="font15">virus </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">HCV-associated </span>
   <span class="font15">HCV-related </span>
   <span class="font15">infection </span>
   <span class="font14">mixed </span>
   <span class="font14">associated </span>
   <span class="font14">cryoglobulinemia </span>
   <span class="font14">response </span>
   <span class="font14">RTX </span>
   <span class="font13">vasculitis </span>
   <span class="font13">DAAs. </span>
   <span class="font13">agents </span>
   <span class="font13">immunosuppressive </span>
   <span class="font13">CKD </span>
   <span class="font13">Kidney </span>
   <span class="font13">mg) </span>
   <span class="font13">mg/ </span>
   <span class="font13">renal </span>
   <span class="font12">&amp;lt; </span>
   <span class="font12">IFN </span>
   <span class="font12">and/or </span>
   <span class="font12">immune </span>
   <span class="font12">HCV. </span>
   <span class="font12">Table </span>
   <span class="font12">Treatment </span>
   <span class="font12">frequency </span>
   <span class="font12">proteinuria </span>
   <span class="font12">regimens </span>
   <span class="font12">treated </span>
   <span class="font12">viral </span>
   <span class="font12">Disease </span>
   <span class="font12">HCV-induced </span>
   <span class="font12">direct-acting </span>
   <span class="font12">genotype </span>
   <span class="font12">membranoproliferative </span>
   <span class="font12">patient </span>
   <span class="font12">px; </span>
   <span class="font12">received </span>
   <span class="font12">review </span>
   <span class="font12">rituximab </span>
   <span class="font12">studies </span>
   <span class="font12">virological </span>
   <span class="font12">{font-family </span>
   <span class="font12">Glomerular </span>
   <span class="font12">However, </span>
   <span class="font12">RNA </span>
   <span class="font12">SVR </span>
   <span class="font12">font-size </span>
   <span class="font12">given </span>
   <span class="font12">important </span>
   <span class="font12">noted </span>
   <span class="font12">observed </span>
   <span class="font12">plus </span>
   <span class="font12">serum </span>
   <span class="font12">severe </span>
   <span class="font12">stage </span>
   <span class="font12">syndrome </span>
   <span class="font12">therapies </span>
   <span class="font11">DAA-based </span>
   <span class="font11">Hepatitis </span>
   <span class="font11">Patients </span>
   <span class="font11">[,]. </span>
   <span class="font11">adverse </span>
   <span class="font11">combinations </span>
   <span class="font11">complexes </span>
   <span class="font11">deposits </span>
   <span class="font11">disease. </span>
   <span class="font11">double; </span>
   <span class="font11">following </span>
   <span class="font11">general </span>
   <span class="font11">shows </span>
   <span class="font11">sustained </span>
   <span class="font11">systematic </span>
   <span class="font11">type </span>
   <span class="font11">virus-associated </span>
   <span class="font11">Antiviral </span>
   <span class="font11">HCV-Related </span>
   <span class="font11">Nephrotic </span>
   <span class="font11">RBV </span>
   <span class="font11">[], </span>
   <span class="font11">activity </span>
   <span class="font11">baseline </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cause </span>
   <span class="font11">course </span>
   <span class="font11">damage </span>
   <span class="font11">direct </span>
   <span class="font11">dose </span>
   <span class="font11">drugs </span>
   <span class="font11">efficacy </span>
   <span class="font11">events </span>
   <span class="font11">factor </span>
   <span class="font11">frequent </span>
   <span class="font11">including </span>
   <span class="font11">liver </span>
   <span class="font11">mL/min/. </span>
   <span class="font11">manifestations </span>
   <span class="font11">population </span>
   <span class="font11">solid; </span>
   <span class="font11">symptomatic </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(Table </span>
   <span class="font11">CI, </span>
   <span class="font11">Clinical </span>
   <span class="font11">Cryoglobulinemic </span>
   <span class="font11">HCV-MCS </span>
   <span class="font11">HCV-infected </span>
   <span class="font11">MCS </span>
   <span class="font11">Mesangial </span>
   <span class="font11">according </span>
   <span class="font11">acting </span>
   <span class="font11">additional </span>
   <span class="font11">administration </span>
   <span class="font11">based </span>
   <span class="font11">bold </span>
   <span class="font11">cells </span>
   <span class="font11">courier; </span>
   <span class="font11">data </span>
   <span class="font11">diseases </span>
   <span class="font11">eGFR </span>
   <span class="font11">effective </span>
   <span class="font11">elbasvir/grazoprevir </span>
   <span class="font11">em; </span>
   <span class="font11">estimate </span>
   <span class="font11">haematuria </span>
   <span class="font11">high </span>
   <span class="font11">includes </span>
   <span class="font11">increased </span>
   <span class="font11">inhibitors </span>
   <span class="font11">isolated </span>
   <span class="font11">large </span>
   <span class="font11">long-term </span>
   <span class="font11">low </span>
   <span class="font11">management </span>
   <span class="font11">mono-therapy </span>
   <span class="font11">number </span>
   <span class="font11">pathogens---t_Table </span>
   <span class="font11">patients) </span>
   <span class="font11">pt;} </span>
   <span class="font11">rates </span>
   <span class="font11">recent </span>
   <span class="font11">regimen </span>
   <span class="font11">relationship </span>
   <span class="font11">remission </span>
   <span class="font11">report </span>
   <span class="font11">reports </span>
   <span class="font11">syndrome, </span>
   <span class="font11">transplant </span>
   <span class="font11">unique </span>
   <span class="font11">vasculitic </span>
  </p>
 </body>
</html>
